Design of dry powder inhalers to improve patient outcomes: it’s not just about the device

References

• Borgström L, Clark A, Olsson B. Introduction. 1000 years of pharmaceutical aerosols. What remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S1–S4. doi: 10.1089/jamp.2010.0848
   PubMedGoogle Scholar
• Smith IJ, Bell J, Bowman N, et al. Inhaler devices: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2):S25–S37. doi: 10.1089/jamp.2010.0853
   PubMedGoogle Scholar
• Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin Drug Deliv. 2014;11:365–378. doi: 10.1517/17425247.2014.873402
   PubMed Web of Science ®Google Scholar
• Pritchard JN, Giles RD. Opportunities in respiratory drug delivery. Ther Deliv. 2014;5:1261–1273. doi: 10.4155/tde.14.78
   PubMedGoogle Scholar
• Pritchard JN What are meaningful device improvements for patients, providers, and payers? In: RN Dalby, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Traini D, editors. Respiratory drug delivery Vol. 1. Richmond (VA): Virginia Commonwealth University; 2014. p. 217–227.
   Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022. doi: 10.1007/s11095-007-9475-1
   PubMed Web of Science ®Google Scholar
• Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38:728–746. doi: 10.1016/j.jaerosci.2007.04.005
   Web of Science ®Google Scholar
• Weers JG, Tarara TE. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv. 2014;8:647–661. doi: 10.4155/tde.14.3
   Google Scholar
• Weers JG, Miller DP, Tarara TE. Spray-dried PulmoSphere™ formulations for inhalation comprising crystalline drug particles. AAPS Pharm Sci Tech. 2019;20:103. doi: 10.1208/s12249-018-1280-0
   PubMed Web of Science ®Google Scholar
• Glusker M, Axford G, Le J, et al. USSC-003: a modular breath-actuated multi-dose dry powder inhaler system with telehealth capability. In: Dalby R, Byron P, Peart J, Suman J, Farr S, Young P Traini D, editors. Respiratory drug delivery. Vol. 3. Richmond (VA): Virginia Commonwealth University; 2016. p. 449–453.
   Google Scholar
• Glusker M, Chiao A, Axford G, et al. Multidose inhaler. U.S. Patent 10,967,139 B2. 2021.
   Google Scholar
• Serafin C, Maltz D, Glusker M, et al. Aspirations for usability: successfully including human factors in the design of the USSC-003 inhaler. In: Dalby R, Byron P, Peart J, Suman J, Farr S, Young P Traini D, editors. Respiratory drug delivery. Vol. 3. Richmond (VA): Virginia Commonwealth University; 2016. p. 477–480.
   Google Scholar
• Van Ganse E, Mork AC, Osman LM, et al. Factors affecting adherence to asthma treatment: patients and physician perspectives. Prim Care Respir J. 2003;12(2):46–51. doi: 10.1038/pcrj.2003.17
   PubMedGoogle Scholar
• FDA Guidance Document. Applying human factors and usability engineering to medical devices. 2016. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices.
   Google Scholar
• Lavorini F, Magnan A, Christophe Dubus J, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir med. 2008;102:593–604. doi: 10.1016/j.rmed.2007.11.003
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308–1331. doi: 10.1183/09031936.00166410
   PubMed Web of Science ®Google Scholar
• Kocks J, Bosnic-Anticevich S, van Cooten J, et al. Identifying critical inhalation technique errors in dry powder inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med. 2023;23:302. doi: 10.1186/s12890-023-02566-6
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Seheult J, Sadasivuni N, et al. The impact of common inhaler errors on drug delivery: investigating critical errors with a dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2017;30:247–255. doi: 10.1089/jamp.2016.1334
   PubMed Web of Science ®Google Scholar
• Clark AR. The role of inspiratory pressures in determining the flow rates though dry powder inhalers: a review. Curr Pharm Des. 2015;21(27):3974–3983. doi: 10.2174/1381612821666150820105800
   PubMed Web of Science ®Google Scholar
• Clark AR, Weers JG, Dhand R. The confusing world of dry powder inhalers: It is all about inspiratory pressures, not inspiratory flow rates. J Aerosol Med Pulm Drug Deliv. 2020;33:1–11. doi: 10.1089/jamp.2019.1556
   PubMed Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers — implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110. doi: 10.1089/jam.1993.6.99
   PubMedGoogle Scholar
• Harris D. The advantages of designing high resistance swirl chambers for use in dry powder inhalers. ONdrugDelivery. 2015;57:10–13.
   Google Scholar
• De Koning JP, Van der Mark TW, Coenegracht PMJ, et al. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm. 2002;234:257–266. doi: 10.1016/S0378-5173(01)00969-3
   PubMed Web of Science ®Google Scholar
• Azouz W, Chetcuti P, Hosker H, et al. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. BMC Pulm Med. 2015;15(1):47. doi: 10.1186/s12890-015-0043-x
   PubMedGoogle Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. doi: 10.1186/s12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19:456–465. doi: 10.1089/jam.2006.19.456
   PubMedGoogle Scholar
• Sahay S, Holy R, Lyons S, et al. Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOS™ dry powder inhaler device. Pulm Circ. 2021;11:1–9. doi: 10.1177/2045894020985345
   Web of Science ®Google Scholar
• Weers JG, Ung K, Le J, et al. Dose emission characteristics of placebo PulmoSphere ® particles are unaffected by a subject’s inhalation maneuver. J Aerosol Med Pulm Drug Deliv. 2013;26(1):56–68. doi: 10.1089/jamp.2012.0973
   PubMed Web of Science ®Google Scholar
• Ament BJ, Weers JG, Maltz DS, et al. Analysis of inhalation profiles in elderly COPD subjects. In: Dalby R, Byron P, Peart J, Suman J, Farr S Young P, editors. Respiratory drug delivery. Vol. 3. Richmond (VA): Virginia Commonwealth University; 2012. p. 613–616.
   Google Scholar
• Broeders MEAC, Molema J, Hop WCJ, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir med. 2004;98:1173–1179. doi: 10.1016/j.rmed.2004.04.010
   PubMed Web of Science ®Google Scholar
• Corradi M, Chrystyn H, Cosio BG, et al. Nexthaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclomethasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv. 2014;11(9):1497–1506. doi: 10.1517/17425247.2014.928282
   PubMed Web of Science ®Google Scholar
• Chetta A, Yorgancioglu A, Scuri M, et al. Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD. BMC Pulm Med. 2021;21:65. doi: 10.1186/s12890-021-01430-9
   PubMed Web of Science ®Google Scholar
• Clark AR, Chambers CB, Muir D, et al. The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5 μ m) bolus aerosols. J Aerosol Med. 2007;20(1):75–82. doi: 10.1089/jam.2006.0557
   PubMedGoogle Scholar
• Everard ML, Devadason SG, Le Souef PN. Flow early in the inspiratory maneuver affects the aerosol particle size distribution from a turbuhaler. Respir med. 1997;91(10):624–628. doi: 10.1016/s0954-6111(97)90009-3
   PubMed Web of Science ®Google Scholar
• Haynes A, Geller D, Weers J, et al. Inhalation of tobramycin using simulated cystic fibrosis patient profiles. Pediatr Pulmonol. 2016;51:1159–1167. doi: 10.1002/ppul.23451
   PubMed Web of Science ®Google Scholar
• Farkas A, Lewis D, Church T, et al. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhaler. Int J Pharm. 2017;533(1):225–235. doi: 10.1016/j.ijpharm.2017.09.057
   PubMedGoogle Scholar
• Vartiainen VA, Lavorini F, Murphy AC, et al. High inhaler resistance does not limit successful inspiratory maneuver among patients with asthma or COPD. Expert Opin Drug Deliv. 2023;20:385–393. doi: 10.1080/17425247.2023.2179984
   PubMed Web of Science ®Google Scholar
• Weers JG, Son Y-J, Glusker M, et al. Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract? J Aerosol Med Pulm Drug Deliv. 2019;32:55–69. doi: 10.1089/jamp.2018.1497
   PubMed Web of Science ®Google Scholar
• Cardwell ND, Zee J, Kadrichu NP, et al. Flow field characterization of three dry powder inhalers. In: Dalby R, Byron P, Peart J, Suman J, Farr S, Young P Traini D, editors. Respiratory drug delivery. Vol. 2. Richmond (VA): Virginia Commonwealth University; 2014. p. 501–504.
   Google Scholar
• Cook CD, Mead J, Orzalesi MM. Static volume-pressure characteristics of the respiratory system during maximal efforts. J Appl Physiol. 1964;19(5):1016–1022. doi: 10.1152/jappl.1964.19.5.1016
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–254. doi: 10.1089/089426803769017613
   PubMedGoogle Scholar
• Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and associated with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–1081. doi: 10.1016/j.jaip.201701.004
   PubMed Web of Science ®Google Scholar
• Farkas A, Tomisa G, Kugler S, et al. The effect of exhalation before the inhalation of dry powder aerosol drugs, emitted doses, and aerosol size distributions. Int J Pharm. 2023;5:100167. doi: 10.1016/j.ijpx.2023.100167
   Google Scholar
• Weers JG, Clark AR. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers. Pharm Res. 2017;34(3):507–528. doi: 10.1007/s-11095-016-2050-x
   PubMed Web of Science ®Google Scholar
• DeBoer AH, Chan H-K, Price R. A critical review on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv Drug Deliv Rev. 2012;64(3):257–274. doi: 10.1016/j.addr.2011.04.004
   PubMed Web of Science ®Google Scholar
• Hebbink G, Jaspers M, Peters H, et al. Recent developments in lactose blends for carrier-based dry powder inhalation. Adv Drug Deliv Rev. 2022;189:114527. doi: 10.1016/j.addr.2022.114527
   PubMed Web of Science ®Google Scholar
• Begat P, Morton DAV, Staniforth JN, et al. The cohesive adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm Res. 2004;21(9):1591–1597. doi: 10.1023/b:pham.0000041453.24419.8a
   PubMed Web of Science ®Google Scholar
• Darquenne C. Deposition mechanisms. J Aerosol Med Pulm Drug Deliv. 2020;33:181–185. doi: 10.1089/jamp.2020.29029.cd
   PubMed Web of Science ®Google Scholar
• Darquenne C, vanErtbruggen C, Prisk GK. Convective flow dominates aerosol delivery to the lung segments. J Appl Physiol. 2011;111:48–54. doi: 10.1152/japplphysiol.00796.2010
   PubMed Web of Science ®Google Scholar
• Martin AR, Finlay WH. A general, algebraic equation for predicting total respiratory tract deposition of micrometer-sized aerosol particles in humans. J Aerosol Sci. 2007;38(2):246–253. doi: 10.1016/j.jaerosci.2006.11.002
   Web of Science ®Google Scholar
• Stahlhofen W, Rudolf G, James AC. Intercomparison of experimental regional deposition data. J Aerosol Med. 1989;2(3):285–308. doi: 10.1089/jam.1989.2.285
   Google Scholar
• Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473–483. doi: 10.1089/jam.2006.19.473
   PubMedGoogle Scholar
• Clark AR, Egan M. Modelling the deposition of inhaled powdered drug aerosols. J Aerosol Sci. 1994;25(1):175–186. doi: 10.1016/0021-8502
   Web of Science ®Google Scholar
• Weers JG, Clark AR, Rao N, et al. In vitro–in vivo correlations observed with indacaterol-based formulations delivered with the breezhaler ®. J Aerosol Med Pulm Drug Deliv. 2015;28(4):268–280. doi: 10.1089/jamp.2014.1178
   PubMed Web of Science ®Google Scholar
• Shur J, Price R, Lewis D, et al. From single excipients to dual excipient platforms in dry powder inhaler products. Int J Pharm. 2016;514:374–383. doi: 10.1016/j.ijpharm.2016.05.057
   PubMedGoogle Scholar
• Begat P, Price R, Harris H, et al. The influence of force control agents on the cohesive-adhesive energy balance in dry powder inhaler formulations. Kona. 2005;23:109–121. doi: 10.14356/kona.2005014
   Google Scholar
• Egan M, Nixon WA. A model of aerosol deposition in the lung for use in inhalation dose assessments. Radiat Prot Dosim. 1985;11:5–17. doi: 10.1016/0021-8502(94)90189-9
   Web of Science ®Google Scholar
• Miller DP, Tarara TE, Weers JG. Targeting of inhaled therapeutics to the small airways: nanoleucine carrier formulations. Pharmaceutics. 2021;13:1855. doi: 10.3390/pharmaceutics13111855
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Respiratory tract deposition of HFA–beclomethasone and HFA–fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv. 2016;29:127–133. doi: 10.1089/jamp.2014.1199
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pedersen S, Usmani OS. Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151:1345–1355. doi: 10.1016/j.chest.2016.07.035
   PubMed Web of Science ®Google Scholar
• Usmani OS. Treating the small airways. Respiration. 2012;84:441–453. doi: 10.1159/000343629
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868–1871. doi: 10.1126/science.276.5320.1868
   PubMed Web of Science ®Google Scholar
• Stevenson C, Bennett D. Development of Exubera insulin pulmonary delivery system. In: das Neves J, and Sarmento B, editors. Mucosal delivery of biopharmaceuticals. New York (NY): Springer; 2014. p. 461–481. Chapter 21.
   Google Scholar
• Parks DJ, Rocchio MJ, Naydo K, et al. US Patent 6,267,155. 2001.
   Google Scholar
• Stout G, Pham X, Rocchio MJ, et al. Powder filling apparatus and methods for their use. US Patent 6,182,712. 2001.
   Google Scholar
• Lechuga-Ballesteros D, Charan C, Stults CL, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97(1):287–302. doi: 10.1002/jps.21078
   PubMed Web of Science ®Google Scholar
• Ung KT, Rao N, Weers JG, et al. Design of spray-dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose. Int J Pharm. 2016;511(2):1070–1079. doi: 10.1016/j.ijpharm.2016.07.073
   PubMedGoogle Scholar
• Geller D, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175–182. doi: 10.1089/jamp.2010.0855
   PubMed Web of Science ®Google Scholar
• McShane PJ, Weers JG, Tarara TE, et al. Ciprofloxacin dry powder for inhalation (CIP): technical design and features of an efficient drug-device combination. Pulm Pharmacol Ther. 2018;50:72–79. doi: 10.1016/j.pupt.2018.03.005
   PubMed Web of Science ®Google Scholar
• Weers JG. Comparison of phospholipid-based particles for sustained release of ciprofloxacin following pulmonary administration to bronchiectasis patients. Pulm Ther. 2019;5:127–150. doi: 10.1007/s41030-019-00104-6
   PubMedGoogle Scholar
• Kugler AR, Lee JD, Samford LK, et al. Clinical pharmacokinetics (PK) following multiple doses of amphotericin B inhalation powder (ABIP). Focus on fungal infections (FoFI) 17. Abstract P-0032. 2007. p. 225–226.
   Google Scholar
• Weers JG, Tarara T, Teung P, et al. Solving the particle adhesion paradox: respirable agglomerates of micronized drugs and porous (microcarrier) particles. In: Dalby R, Byron P, Peart J, Suman J, Young P Traini D, editors. Respiratory drug delivery Europe. Vol. 1. Richmond (VA): Virginia Commonwealth University; 2015. p. 177–185.
   Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Co-suspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from metered dose inhalers. Langmuir. 2012;28(42):15015–15023. doi: 10.1021/la302281n
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, et al. Novel co-suspension metered dose inhalers for combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718. doi: 10.4155/fmc.11.133
   PubMed Web of Science ®Google Scholar
• Usmani OS, Roche N, Jenkins M, et al. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. Int J COPD. 2021;16:113–124. doi: 10.2147/COPD.S274846
   Google Scholar
• Ferguson GT, Hickey AJ, Dwivedi S. Co-suspension delivery technology in pressurized metered dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir med. 2018;134:16–23. doi: 10.1016/j.rmed.2017.09.012
   PubMed Web of Science ®Google Scholar
• Mahler DA, Halpin DMG. Peak inspiratory flow as a predictive therapeutic biomarker in COPD. Chest. 2021;160:491–498. doi: 10.1016/j.chest2021.03.049
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30:381–387. doi: 10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Christensen MC, Anthony SD, Roth EA. Seeing what’s next. Cambridge (MA): Harvard Business School Press; 2004.
   Google Scholar